vs
Side-by-side financial comparison of NOODLES & Co (NDLS) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
NOODLES & Co is the larger business by last-quarter revenue ($122.1M vs $103.7M, roughly 1.2× Twist Bioscience Corp). NOODLES & Co runs the higher net margin — -7.5% vs -29.4%, a 21.9% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs -4.1%). NOODLES & Co produced more free cash flow last quarter ($-2.8M vs $-34.8M).
Noodles & Company is an American fast-casual restaurant that offers international and American noodle dishes in addition to soups and salads. Noodles & Company was founded in 1995 by Aaron Kennedy and is headquartered in Broomfield, Colorado. The company went public in 2013 and recorded a $457 million revenue in 2017. In mid-2022, there were 458 Noodles & Company locations across 31 states.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
NDLS vs TWST — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $122.1M | $103.7M |
| Net Profit | $-9.2M | $-30.5M |
| Gross Margin | — | 52.0% |
| Operating Margin | -5.2% | -31.7% |
| Net Margin | -7.5% | -29.4% |
| Revenue YoY | -4.1% | 16.9% |
| Net Profit YoY | 32.8% | 3.4% |
| EPS (diluted) | $-0.20 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $103.7M | ||
| Q3 25 | $122.1M | — | ||
| Q2 25 | $123.8M | — | ||
| Q4 24 | $122.8M | — | ||
| Q3 24 | $127.4M | — | ||
| Q2 24 | $121.4M | — | ||
| Q1 24 | $124.3M | — | ||
| Q4 23 | $127.9M | — |
| Q4 25 | — | $-30.5M | ||
| Q3 25 | $-9.2M | — | ||
| Q2 25 | $-9.1M | — | ||
| Q4 24 | $-6.8M | — | ||
| Q3 24 | $-13.6M | — | ||
| Q2 24 | $-6.1M | — | ||
| Q1 24 | $-6.1M | — | ||
| Q4 23 | $700.0K | — |
| Q4 25 | — | 52.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q4 25 | — | -31.7% | ||
| Q3 25 | -5.2% | — | ||
| Q2 25 | -5.2% | — | ||
| Q4 24 | -3.9% | — | ||
| Q3 24 | -9.0% | — | ||
| Q2 24 | -3.4% | — | ||
| Q1 24 | -3.7% | — | ||
| Q4 23 | 1.6% | — |
| Q4 25 | — | -29.4% | ||
| Q3 25 | -7.5% | — | ||
| Q2 25 | -7.3% | — | ||
| Q4 24 | -5.5% | — | ||
| Q3 24 | -10.7% | — | ||
| Q2 24 | -5.1% | — | ||
| Q1 24 | -4.9% | — | ||
| Q4 23 | 0.5% | — |
| Q4 25 | — | $-0.50 | ||
| Q3 25 | $-0.20 | — | ||
| Q2 25 | $-0.20 | — | ||
| Q4 24 | $-0.15 | — | ||
| Q3 24 | $-0.30 | — | ||
| Q2 24 | $-0.14 | — | ||
| Q1 24 | $-1.64 | — | ||
| Q4 23 | $0.02 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.7M | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-38.9M | $456.1M |
| Total Assets | $280.6M | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $197.9M | ||
| Q3 25 | $4.7M | — | ||
| Q2 25 | $1.4M | — | ||
| Q4 24 | $3.3M | — | ||
| Q3 24 | $1.8M | — | ||
| Q2 24 | $1.3M | — | ||
| Q1 24 | $3.0M | — | ||
| Q4 23 | $2.5M | — |
| Q4 25 | — | $456.1M | ||
| Q3 25 | $-38.9M | — | ||
| Q2 25 | $-13.9M | — | ||
| Q4 24 | $3.7M | — | ||
| Q3 24 | $9.6M | — | ||
| Q2 24 | $21.9M | — | ||
| Q1 24 | $27.2M | — | ||
| Q4 23 | $32.5M | — |
| Q4 25 | — | $638.1M | ||
| Q3 25 | $280.6M | — | ||
| Q2 25 | $319.4M | — | ||
| Q4 24 | $340.5M | — | ||
| Q3 24 | $346.3M | — | ||
| Q2 24 | $360.4M | — | ||
| Q1 24 | $368.1M | — | ||
| Q4 23 | $368.8M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.3M | $-24.8M |
| Free Cash FlowOCF − Capex | $-2.8M | $-34.8M |
| FCF MarginFCF / Revenue | -2.3% | -33.5% |
| Capex IntensityCapex / Revenue | 5.8% | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-7.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-24.8M | ||
| Q3 25 | $4.3M | — | ||
| Q2 25 | $4.0M | — | ||
| Q4 24 | $5.8M | — | ||
| Q3 24 | $4.7M | — | ||
| Q2 24 | $7.0M | — | ||
| Q1 24 | $164.0K | — | ||
| Q4 23 | $16.9M | — |
| Q4 25 | — | $-34.8M | ||
| Q3 25 | $-2.8M | — | ||
| Q2 25 | $1.1M | — | ||
| Q4 24 | $-1.3M | — | ||
| Q3 24 | $-4.5M | — | ||
| Q2 24 | $-1.6M | — | ||
| Q1 24 | $-15.2M | — | ||
| Q4 23 | $4.1M | — |
| Q4 25 | — | -33.5% | ||
| Q3 25 | -2.3% | — | ||
| Q2 25 | 0.9% | — | ||
| Q4 24 | -1.1% | — | ||
| Q3 24 | -3.5% | — | ||
| Q2 24 | -1.4% | — | ||
| Q1 24 | -12.2% | — | ||
| Q4 23 | 3.2% | — |
| Q4 25 | — | 9.6% | ||
| Q3 25 | 5.8% | — | ||
| Q2 25 | 2.4% | — | ||
| Q4 24 | 5.8% | — | ||
| Q3 24 | 7.2% | — | ||
| Q2 24 | 7.1% | — | ||
| Q1 24 | 12.3% | — | ||
| Q4 23 | 10.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | 24.21× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NDLS
| Food And Beverage | $119.6M | 98% |
| Franchise | $2.5M | 2% |
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
